November 9, 2020 10:21 AM EST
R&D
Pharma

Bris­tol My­ers posts an­oth­er win for their Ote­zla com­peti­tor, this time with PhII da­ta in pso­ri­at­ic arthri­tis

Max Gelman

Senior Editor

Less than a week af­ter claim­ing a Phase III vic­to­ry over Am­gen’s Ote­zla in pso­ri­a­sis, Bris­tol My­ers Squibb has more pos­i­tive da­ta out in pso­ri­at­ic …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

J&J part­ners on STAT6; As­traZeneca, Dai­ichi with­draw lung can­cer drug EMA app

FDA ap­proves sub­cu­ta­neous ver­sion of Bris­tol My­er­s' Op­di­vo

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

A service from the Financial Times